公开(公告)号：US20240336977A1

公开(公告)日：2024-10-10

申请号：US18629544

申请日：2024-04-08

Applicant: West Virginia University Board of Governors on behalf of West Virginia University

Inventor： Nancy Lan Guo

IPC: C12Q1/6886 ,  A61K31/166 ,  A61K31/4025 ,  A61K31/4178 ,  A61K31/506 ,  A61K31/517 ,  A61K31/553 ,  A61K31/704

CPC classification number: C12Q1/6886 ,  A61K31/166 ,  A61K31/4025 ,  A61K31/4178 ,  A61K31/506 ,  A61K31/517 ,  A61K31/553 ,  A61K31/704 ,  C12Q2600/158 ,  C12Q2600/178

Abstract: This invention identifies sets of microRNAs (miRNAs) that classified breast cancer or lung cancer tumors from normal lung tissues with a high accuracy in patients. The findings also allowed identification of methods for improving lung or breast cancer diagnosis, optimizing treatment selection, and discovering new drug options for better patient outcomes.

公开(公告)号：US20240325380A1

公开(公告)日：2024-10-03

申请号：US18741475

申请日：2024-06-12

Applicant: TMTRx, Inc.

Inventor： Phillip R. Torralva

IPC: A61K31/485 ,  A61K31/137 ,  A61K31/18 ,  A61K31/225 ,  A61K31/40 ,  A61K31/4166 ,  A61K31/4178 ,  A61K31/454 ,  A61K31/46 ,  A61K31/517 ,  A61K31/5377 ,  A61K31/5517 ,  A61P25/36

CPC classification number: A61K31/485 ,  A61K31/137 ,  A61K31/18 ,  A61K31/225 ,  A61K31/40 ,  A61K31/4166 ,  A61K31/4178 ,  A61K31/454 ,  A61K31/46 ,  A61K31/517 ,  A61K31/5377 ,  A61K31/5517 ,  A61P25/36

Abstract: Compositions are provided including a Mu opioid receptor antagonist, and an α2-adrenergic receptor agonist; or an α1 adrenergic receptor antagonist, together with one or more of a mu (or opioid receptor subtype) antagonist or agonist, (2) a vasopressor, (3) an anticholinergic agent and/or cholinergic agents, (4) a combined alpha-1 adrenergic antagonist and anticholinergic, (5) a paralytic or muscle relaxant, (6) a respiratory accelerant, (7) a GABA complex antagonist, (8) an anti-seizure/membrane stabilizer agent, (9) an α1 adrenergic receptor agonist, and/or (10) an α2 adrenergic receptor agonist; and a pharmaceutically acceptable carrier. Also provided are methods of preventing or reversing effects in a subject (including muscle and chest wall rigidity, laryngospasm, WCS, and/or respiratory depression) arising from intentional or accidental opioid or opiate exposure.

公开(公告)号：US20240287194A1

公开(公告)日：2024-08-29

申请号：US18289836

申请日：2022-05-13

Applicant: The General Hospital Corporation

Inventor： Shadmehr Demehri

IPC: C07K16/28 ,  A61K31/192 ,  A61K31/4178 ,  A61K39/00 ,  A61P35/00

CPC classification number: C07K16/2848 ,  A61K31/192 ,  A61K31/4178 ,  A61P35/00 ,  C07K16/2803 ,  C07K16/2842 ,  A61K2039/505 ,  C07K2317/76

Abstract: Elucidating the mechanism that underlies tissue-specific NK cell responses will have major implications in cancer immunology, transplant biology and virology. Provided herein are compositions and methods for of treating a subject who has a solid tumor or who has a viral infection, or promoting cytotoxicity of natural killer (NK) cells in a subject, using (i) blocking antibodies to ECM components and/or (ii) inhibitors of collagen deposition or production.

公开(公告)号：US20240279220A1

公开(公告)日：2024-08-22

申请号：US18593686

申请日：2024-03-01

Applicant: Genzyme Corporation

Inventor： Junkai Liao ,  Mark Munson ,  Sukanthini Thurairatnam ,  Bradford Hirth ,  Zhongli Gao ,  Gregory Hurlbut ,  David Borcherding ,  Matthieu Barrague ,  Timothy Alan Gillespy ,  Alexandre Gross ,  Andrew Good ,  Roy Vaz ,  Jinyu Liu ,  Yi Li ,  Markus Metz ,  Anatoly Ruvinsky ,  Claude Barberis

IPC: C07D417/14 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/4178 ,  A61K31/4196 ,  A61K31/422 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/675 ,  C07D401/14 ,  C07D403/12 ,  C07D405/14 ,  C07D409/14 ,  C07D413/12 ,  C07D417/12 ,  C07F9/6503

CPC classification number: C07D417/14 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/4178 ,  A61K31/4196 ,  A61K31/422 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/675 ,  C07D401/14 ,  C07D403/12 ,  C07D405/14 ,  C07D409/14 ,  C07D413/12 ,  C07D417/12 ,  C07F9/65031

Abstract: The invention relates to heterocyclic compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.

公开(公告)号：US20240277613A1

公开(公告)日：2024-08-22

申请号：US18641775

申请日：2024-04-22

Applicant: Infirst Healthcare Limited

Inventor： Robin M. Bannister ,  John Brew ,  RICHARD R. REILEY, III ,  Wilson Caparros Wanderley

IPC: A61K9/08 ,  A61K9/14 ,  A61K31/12 ,  A61K31/137 ,  A61K31/167 ,  A61K31/19 ,  A61K31/192 ,  A61K31/196 ,  A61K31/201 ,  A61K31/216 ,  A61K31/25 ,  A61K31/337 ,  A61K31/357 ,  A61K31/366 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/522 ,  A61K31/60 ,  A61K31/616 ,  A61K31/704 ,  A61K47/10 ,  A61K47/14

CPC classification number: A61K9/08 ,  A61K9/148 ,  A61K31/12 ,  A61K31/137 ,  A61K31/167 ,  A61K31/192 ,  A61K31/196 ,  A61K31/216 ,  A61K31/357 ,  A61K31/366 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/522 ,  A61K31/60 ,  A61K31/616 ,  A61K47/10 ,  A61K47/14 ,  A61K31/19 ,  A61K31/201 ,  A61K31/25 ,  A61K31/337 ,  A61K31/704

Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.

公开(公告)号：US20240262831A1

公开(公告)日：2024-08-08

申请号：US18257798

申请日：2021-12-17

Applicant: VOVA IDA THERAPEUTICS, INC. ,  THE SCRIPPS RESEARCH INSTITUTE

Inventor： Thomas D. BANNISTER ,  Corinne LASMEZAS ,  Minghai ZHOU ,  Anna Albertson

IPC: C07D487/04 ,  A61K31/4178 ,  A61K31/4365 ,  A61K31/4709 ,  A61K31/519 ,  C07D401/12 ,  C07D405/12 ,  C07D495/04

CPC classification number: C07D487/04 ,  A61K31/4178 ,  A61K31/4365 ,  A61K31/4709 ,  A61K31/519 ,  C07D401/12 ,  C07D405/12 ,  C07D495/04

Abstract: Provided are, inter alia, compounds having a structure of Formulae (X), (I) to (XIII) or a subordinate structure thereof, composition including the same and methods of use.

公开(公告)号：US20240254108A1

公开(公告)日：2024-08-01

申请号：US18289872

申请日：2022-04-19

Applicant: BEAD TECH INC. ,  SOGANG UNIVERSITY R&DB FOUNDATION

Inventor： Yoon Sik LEE ,  Seok In KIM ,  Bong Gun JU ,  Ha Yan JEONG ,  Myeongok KIM

IPC: C07D403/10 ,  A61K31/4178 ,  A61P17/00

CPC classification number: C07D403/10 ,  A61K31/4178 ,  A61P17/00

Abstract: The present invention relates to a compound containing a pyrrolidine moiety as a linker or a pharmaceutically acceptable salt thereof. The present invention also relates to a composition for preventing and treatment of the respiratory diseases or the skin conditions such as atopy and psoriasis and bronchial diseases, including the compound as an active ingredient.

公开(公告)号：US12049459B1

公开(公告)日：2024-07-30

申请号：US18241394

申请日：2023-09-01

Applicant: KING FAISAL UNIVERSITY

Inventor： Hany Mohamed Abd El-Lateef Ahmed ,  Mai Mostafa Khalaf Ali ,  Antar Ahmed Abdelhamid Ahmed ,  Nawf Esanani ,  Adel A. Marzouk

IPC: A61K31/4439 ,  A61K31/4178 ,  A61P35/00 ,  C07D401/04

CPC classification number: C07D401/04 ,  A61K31/4439 ,  A61P35/00 ,  A61K31/4178

Abstract: A compound 3-(4,5-Diphenyl-2-(pyridin-3-yl)-1H-imidazol-1-yl)-N,N-dimethylpropan-1-amine, its synthesis, and its use as an anticancer agent.

公开(公告)号：US20240247313A1

公开(公告)日：2024-07-25

申请号：US18394729

申请日：2023-12-22

Applicant: University of Virginia Patent Foundation

Inventor： Bankole A. Johnson

IPC: C12Q1/6883 ,  A61K31/4178 ,  A61K45/06 ,  G01N33/68 ,  G01N33/94

CPC classification number: C12Q1/6883 ,  A61K31/4178 ,  A61K45/06 ,  G01N33/6872 ,  G01N33/942 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N2800/307 ,  G01N2800/50

Abstract: The gene responsible for encoding SERT has a functional polymorphism at the 5′-regulatory promoter region, which results in two forms, long (L) and short (S). The LL-genotype is hypothesized to play a key role in the early onset of alcohol use. The present invention discloses the differences in treatment and diagnosis based on the L or short genotypes as well as on a single nucleotide polymorphism of the SERT gene, the 3′ UTR SNP rs1042173. The present invention demonstrates the efficacy of using the drug ondansetron and similar drugs for treatment based on variations in the polymorphisms of the SERT gene as well as methods for diagnosing susceptibility to abuse of alcohol and other addiction-related diseases and disorders.

公开(公告)号：US20240245668A1

公开(公告)日：2024-07-25

申请号：US18625513

申请日：2024-04-03

Applicant: SANTEN PHARMACEUTICAL CO., LTD.

Inventor： Tomoko KIRIHARA ,  Atsushi SHIMAZAKI ,  Masatsugu NAKAMURA

IPC: A61K31/444 ,  A61K31/225 ,  A61K31/4178 ,  A61K31/498 ,  A61K31/5377 ,  A61K31/542 ,  A61K31/551 ,  A61K31/5575 ,  A61K45/06 ,  C07D401/14

CPC classification number: A61K31/444 ,  A61K31/225 ,  A61K31/4178 ,  A61K31/498 ,  A61K31/5377 ,  A61K31/542 ,  A61K31/551 ,  A61K31/5575 ,  A61K45/06 ,  C07D401/14

Abstract: A preventive or therapeutic agent for glaucoma or ocular hypertension includes a combination of isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl) aminomethyl}pyridin-2-ylamino)acetate with one or more other preventive or therapeutic drugs for glaucoma or ocular hypertension, with the proviso that tafluprost is excluded.